The consequences of rheumatoid arthritis: Quality of life measures in the individual patient

被引:1
作者
Pollard, L
Choy, EH
Scott, DL
机构
[1] Kings Coll London, Dept Rheumatol, GKT Sch Med, Weston Educ Ctr, London SE5, England
[2] Kings Coll Hosp London, Dept Rheumatol, London, England
关键词
rheumatoid arthritis; pain; fatigue; depression; disability; health assessment questionnaire;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite conventional treatment, RA still has many deleterious consequences. From the patient's perspective, these include persistent pain, functional disability, fatigue, and depression modified by health beliefs and underlying psychological problems. Disability is a consequence of pain, active synovitis and joint damage. It is usually assessed by self-reported questionnaire ; the Health Assessment Questionnaire (HAQ) remains the dominant disability measure, although generic health measures such as Short Form-36 and Nottingham Health Profile provide similar information. Treatment with disease modifying drugs and biologic agents improves pain, fatigue and disability. We specifically evaluated the effects of both these drugs and also disease duration on disability assessed by HAQ scores, as there is most information on this topic and it is of fundamental importance to patients. In early RA HAQ gives a 'J-shaped' curve; the initial fall is due to the subsequent gradual rise due to the inability of therapy to fully suppress the disease or prevent progressive joint damage. In established RA HAQ scores increase by about 1% annualy and over 25 years average HAQ scores increase by 1.0. Disease modifying drugs and biologics both significantly reduce HAQ scores and the reduction is maintained for 2-5 years. This reduction is seen in both early and established disease. Early steroid therapy has immediate symptomatic treatment, but does not have long-term benefits. Over 5 years the impact of aggressive therapy with disease modifying drugs declines and there is evidence that insufficient treatment is given to many patients with RA. The outcome of RA is greatly improved by current treatment with disease modifying drugs and biologic agents. However, more needs need to be done and achieving better results is enhanced by routinely measuring the impact of the disease in routine practice.
引用
收藏
页码:S43 / S52
页数:10
相关论文
共 105 条
  • [11] How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study
    Birrell, FN
    Hassell, AB
    Jones, PW
    Dawes, PT
    [J]. CLINICAL RHEUMATOLOGY, 2000, 19 (03) : 195 - 199
  • [12] Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
    Boers, M
    Verhoeven, AC
    Markusse, HM
    vandeLaar, MAFJ
    Westhovens, R
    vanDenderen, JC
    vanZeben, D
    Dijkmans, BAC
    Peeters, AJ
    Jacobs, P
    vandenBrink, HR
    Schouten, HJA
    vanderHeijde, DMFM
    Boonen, A
    vanderLinden, S
    [J]. LANCET, 1997, 350 (9074) : 309 - 318
  • [13] Carr A, 2003, J RHEUMATOL, V30, P880
  • [14] Carr AJ, 1996, BRIT J RHEUMATOL, V35, P921
  • [15] Cella D, 2005, J RHEUMATOL, V32, P811
  • [16] DEVELOPMENT OF A FATIGUE SCALE
    CHALDER, T
    BERELOWITZ, G
    PAWLIKOWSKA, T
    WATTS, L
    WESSELY, S
    WRIGHT, D
    WALLACE, EP
    [J]. JOURNAL OF PSYCHOSOMATIC RESEARCH, 1993, 37 (02) : 147 - 153
  • [17] New approaches to understanding the impact of musculoskeletal conditions
    Cieza, A
    Stucki, G
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (02): : 141 - 154
  • [18] Clark P, 2003, J RHEUMATOL, V30, P1584
  • [19] Combe B, 2003, J RHEUMATOL, V30, P2344
  • [20] Performance of a generic health-related quality of life measure in a clinic population with rheumatic disease
    Currey, SS
    Rao, JK
    Winfield, JB
    Callahan, LF
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2003, 49 (05): : 658 - 664